Use of Phenobarbitone for Palliative Sedation in Dyspneic Crises Due to COVID-19 Pneumonia - A Case Series.

Autor:	Sim J; Department of Palliative Medicine, Tan Tock Seng Hospital, Singapore, Singapore., Goh WY; Department of Palliative Medicine, Tan Tock Seng Hospital, Singapore, Singapore., Wiryasaputra L; Department of Palliative Medicine, Tan Tock Seng Hospital, Singapore, Singapore., Hum AY; Department of Palliative Medicine, Tan Tock Seng Hospital, Singapore, Singapore., Neo HY; Department of Palliative Medicine, Tan Tock Seng Hospital, Singapore, Singapore., Poi CH; Department of Palliative Medicine, Tan Tock Seng Hospital, Singapore, Singapore.
Jazyk:	angličtina
Zdroj:	Journal of pain & palliative care pharmacotherapy [J Pain Palliat Care Pharmacother] 2022 Dec; Vol. 36 (4), pp. 242-248. Date of Electronic Publication: 2022 Aug 25.
DOI:	10.1080/15360288.2022.2113596
Abstrakt:	Patients who suffer from dyspnea while dying from COVID-19 are treated with opioids and benzodiazepines. In some instances, patients may experience refractory dyspnea at the end of life. Palliative sedation can be prescribed to alleviate such patients' suffering. We describe two patients being treated for severe COVID-19 pneumonia in a tertiary hospital. Both developed intractable dyspneic crises despite high-dose opioids and benzodiazepines. This led to their requirement of palliative sedation in the general ward using subcutaneous phenobarbitone (phenobarbital). We outline clinical considerations for the use of palliative sedation in COVID-19 related dyspnea. In particular, we discuss the evidence for, benefits and limitations of using phenobarbitone for palliative sedation in COVID-19 patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu